History of Endocrinology as a Medical Specialty

Endocrinology emerged as a distinct medical specialty through a progression of experimental discoveries, clinical observations, and institutional developments spanning roughly 150 years. This page traces the discipline's development from early glandular experiments through the formal recognition of board-certified subspecialty practice in the United States. Understanding this history clarifies why the specialty is structured the way it is, how its diagnostic and therapeutic frameworks were built, and what institutional bodies now govern its standards — topics explored in depth throughout endocrinologyauthority.com.

Definition and Scope

Endocrinology is the branch of medicine concerned with the endocrine system — the network of glands and organs that synthesize and secrete hormones directly into the bloodstream to regulate metabolism, growth, reproduction, and homeostasis. As a formal specialty, its scope encompasses diagnosis and management of conditions arising from hormonal excess, deficiency, or resistance, including disorders of the thyroid, adrenal glands, pituitary gland, gonads, parathyroid glands, and pancreatic islet cells.

The modern specialty's boundaries were not always clearly drawn. For most of the 19th century, glandular diseases fell under the purview of general internal medicine, surgery, or neurology depending on the organ affected. The formal separation of endocrinology into a distinct clinical discipline occurred gradually through the 20th century, driven by landmark physiological discoveries and the development of hormone-based therapies that required specialized expertise to deploy safely.

In the United States, the American Board of Internal Medicine (ABIM) administers subspecialty certification in Endocrinology, Diabetes, and Metabolism — a title that itself reflects the specialty's expanded scope beyond gland pathology to include metabolic disease. Practitioners seeking board certification must complete an accredited fellowship, typically 2 years in duration, after residency training in internal medicine (ABIM).

How It Works

Phase 1: The Experimental Foundation (1849–1902)

The traceable scientific foundation begins with Arnold Adolph Berthold's 1849 transplantation experiment in roosters, which demonstrated that testes produce a blood-borne factor affecting secondary sex characteristics — an early proof of endocrine function predating the term "hormone" by more than 50 years.

In 1855, Claude Bernard introduced the concept of internal secretion (sécrétion interne), proposing that organs release substances directly into the blood. That same year, Thomas Addison at Guy's Hospital in London published a clinical description of adrenal insufficiency — the condition now bearing his name — establishing the first formal clinicopathological link between a gland and a recognizable disease syndrome.

Charles-Édouard Brown-Séquard's 1889 self-injection experiments with testicular extracts, though largely discredited in their specific claims, generated wide scientific interest in organotherapy and stimulated research that would eventually produce viable hormone treatments.

The word "hormone" itself entered medical vocabulary in 1902, coined by William Maddock Bayliss and Ernest Henry Starling at University College London after their discovery of secretin — the first identified gastrointestinal hormone. Starling formally proposed the term in his 1905 Croonian Lecture to the Royal Society, defining it as a chemical messenger produced in one organ and carried by the blood to act on another.

Phase 2: Insulin and the Clinical Turn (1921–1950)

The most consequential single event in endocrinology's clinical history occurred in 1921–1922 at the University of Toronto, where Frederick Banting, Charles Best, James Collip, and John Macleod isolated and purified insulin, enabling the first therapeutic use in a human patient in January 1922. Banting and Macleod received the Nobel Prize in Physiology or Medicine in 1923. Before insulin, type 1 diabetes carried a near-uniform fatal prognosis; the discovery transformed it into a manageable chronic condition.

Between 1930 and 1950, cortisone, thyroid hormone preparations, and estrogen compounds became available therapeutically, each requiring clinical expertise that general internists were not consistently trained to provide.

Phase 3: Formal Specialty Recognition (1950–1980)

The American Thyroid Association, founded in 1923, was among the first professional societies to organize clinicians around an endocrine organ. The Endocrine Society, tracing its origins to the Association for the Study of Internal Secretions founded in 1916, became the principal scientific body representing the specialty (Endocrine Society).

ABIM introduced formal subspecialty certification in endocrinology in 1972, establishing standardized competency requirements that distinguished endocrinologists from general internists managing hormonal disorders. This credentialing structure remains the regulatory backbone of the specialty in the US, directly relevant to the regulatory context for endocrinology that governs modern practice.

Phase 4: Molecular and Technological Expansion (1980–Present)

Recombinant DNA technology transformed the specialty beginning in 1982, when the FDA approved Humulin — the first recombinant human insulin — manufactured by Eli Lilly using Genentech's technology. Radioimmunoassay (RIA), developed by Rosalyn Yalow and Solomon Berson in the late 1950s, had already made precise hormone measurement feasible at the clinical level; Yalow received the Nobel Prize in 1977 for this work.

Molecular genetics subsequently identified receptor mutations, transcription factor defects, and polygenic risk architectures underlying conditions previously classified only by their clinical phenotype.

Common Scenarios

Historically significant conditions that shaped specialty development include:

  1. Adrenal insufficiency (Addison's disease) — described 1855; first treatable with cortisone after 1949
  2. Hypothyroidism (myxedema) — clinically characterized in 1873 by William Gull; thyroid extract therapy introduced 1891
  3. Acromegaly — linked to pituitary pathology by Pierre Marie in 1886
  4. Diabetes mellitus — management transformed by insulin (1922); oral sulfonylureas introduced 1957
  5. Cushing's syndrome — described by Harvey Cushing in 1932; surgically addressable by mid-century

Each of these conditions generated a body of specialized diagnostic and therapeutic knowledge that reinforced the case for separate subspecialty training.

Decision Boundaries

A persistent structural question in the specialty's history concerns the boundary between endocrinology and adjacent disciplines. Three comparisons clarify where these lines fall:

Endocrinology vs. Primary Care: General practitioners manage stable, uncomplicated hormonal conditions — such as well-controlled hypothyroidism on replacement therapy — while endocrinologists take primary responsibility for complex, refractory, or rare presentations. The ABIM subspecialty framework formalizes this division by defining competencies that exceed general internal medicine training.

Pediatric vs. Adult Endocrinology: Pediatric endocrinology is a separate ABIM-recognized subspecialty, reflecting distinct disease spectra — growth disorders, congenital adrenal hyperplasia, and differences in type 1 diabetes presentation — and developmental considerations that require dedicated training. Pediatric endocrinology follows a separate fellowship pathway accredited by the Accreditation Council for Graduate Medical Education (ACGME).

Endocrinology vs. Endocrine Surgery: Surgical management of thyroid nodules, parathyroid adenomas, adrenal tumors, and pituitary lesions falls within surgery subspecialties. Endocrinologists typically manage the pre- and post-operative hormonal aspects and determine operative candidacy, but do not perform the procedures. This shared-care model is codified in clinical guidelines issued by the American Association of Clinical Endocrinology (AACE) and the American Thyroid Association (ATA).

The specialty's trajectory — from isolated organ-level observations in the 1850s to a board-certified discipline with molecular diagnostics and closed-loop insulin delivery systems — reflects consistent pressure from both scientific discovery and the clinical complexity of hormonal disease management.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)